Patents by Inventor Jianrong Lu

Jianrong Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ROBUST OPTIMIZATION DESIGN METHOD FOR MECHANICAL ARM BASED ON HYBRID INTERVAL AND BOUNDED PROBABILISTIC UNCERTAINTIES
    Publication number: 20250094668
    Abstract: A robust optimization design method for a mechanical arm considering hybrid interval and bounded probabilistic uncertainties is provided.
    Type: Application
    Filed: November 25, 2024
    Publication date: March 20, 2025
    Inventors: Jin CHENG, Zhenyu LIU, Deshang PENG, Wei LU, Jianrong TAN
  • Methods and compositions for treating negative-sense single-stranded RNA virus
    Patent number: 12227769
    Abstract: The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: February 18, 2025
    Assignees: The University of Chicago, Nationwide Children's Hospital, The Ohio State University
    Inventors: Jianrong Li, Mark E. Peeples, Chuan He, Stefan Niewiesk, Mijia Lu, Miaoge Xue, Zijie Zhang, Boxuan Zhao
  • Modulating the Activity of Nuclear Receptors in Order to Treat Hypoxia-Related Disorders
    Publication number: 20100210735
    Abstract: The subject invention provides methods for treating hypoxia-related conditions by modulating the activity of certain nuclear receptors. Specifically exemplified herein are materials and methods for treating cancer and other pathological conditions involving hypoxia and/or abnormal or excessive neovascularization.
    Type: Application
    Filed: August 6, 2008
    Publication date: August 19, 2010
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Jianrong Lu
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Publication number: 20090087412
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Application
    Filed: September 2, 2008
    Publication date: April 2, 2009
    Inventors: Eric N. Olson, Jianrong Lu, Timothy McKinsey
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Patent number: 7420100
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: September 2, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventors: Eric N. Olson, Jianrong Lu, Timothy McKinsey
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Publication number: 20050106654
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Application
    Filed: August 8, 2003
    Publication date: May 19, 2005
    Inventors: Eric Olson, Jianrong Lu, Timothy McKinsey
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Patent number: 6632628
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: October 14, 2003
    Assignee: Board of Regents, The University of Texas System
    Inventors: Eric N. Olson, Jianrong Lu, Timothy McKinsey